Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.0	0.946	0.01	-0.0808	1.0	0.958
HCC38	TGX221	1	72	sigmoid	sigmoid	HCC38 TGX-221 0 1 72	8	1.724	Inf	0.938	0.0116	0.289	0.941	5.0	0.676	0.0342	NA	Inf	0.947	0.99	0.289	0.949	5.0	0.672	0.0354	NA
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
Hs 578T	XL147	3		flat	flat	Hs578T pilaralisib 3	8	2.879	Inf	0.971	-0.00618	0.0	0.971	0.01	0.331	0.299	1.0	Inf	0.959	1.01	0.0	0.959	0.01	0.319	0.315	1.0
Hs 578T	XL147	1		flat	flat	Hs578T pilaralisib 1	8	2.013	Inf	0.967	0.00411	0.0	0.967	0.01	0.193	0.525	0.991	Inf	0.967	0.996	0.0	0.967	0.01	0.196	0.519	0.991
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
HCC70	XL147	2	72	flat	flat	HCC70 pilaralisib 0 2 72	8	1.789	Inf	0.966	0.0311	0.0	0.966	0.01	-0.12	1.0	0.965	Inf	0.97	0.973	0.0	0.97	0.01	-0.121	1.0	0.969
Hs 578T	XL147	2		flat	flat	Hs578T pilaralisib 2	8	2.509	Inf	0.976	0.000255	0.0	0.976	0.01	0.435	0.181	0.997	Inf	0.97	1.0	0.0	0.97	0.01	0.432	0.183	0.996
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	1	72	flat	flat	HCC1806 KIN001-244 0 1 72	8	2.742	Inf	0.986	0.0236	0.0	0.986	0.01	-0.0573	1.0	0.979	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.0	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	0.0	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	0.0	1.01	0.01	-0.0552	1.0	0.979
HCC1806	AZD-6482	1	72	flat	flat	HCC1806 AZD6482 0 1 72	8	2.748	Inf	1.0	0.00141	0.0	1.0	0.01	-0.00621	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	0.0	1.02	0.01	-0.00881	1.0	1.0
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)